Fulgent Pharma LLC

TEMPLE CITY, CA · Founded 2015 · CIK 0001671523 · Biotech · Acquired

Nanoencapsulated chemotherapy drugs and novel cancer therapeutics

fulgentpharma.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$5.4M
1 Form D · Apr 2016
126 months since last filing
Contracts
—
No federal contracts on record
Patents
8
0 granted · 8 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$5,400,000
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2469New Echota Biotechnology——
2470Rocket Pharmaceuticals Ltd.—$28M
2471BIOSTRATEGIES LC——
2472Fulgent Pharma LLC—$5.4M
2473Kestrel Therapeutics Inc.—$21M
2474FIBRONOX, L.L.C.——
2475Aulos Bioscience, Inc.—$20M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 1 related persons
  • Ming HsiehDirector · Executive Officer

Patents

USPTO · 0 granted of 8
  • TLR9-TARGETED Therapeuticsapplication
  • Treatment Of Head And Neck Cancer With Pharmaceutical Composition Comprising Nanoparticles Containing Taxaneapplication
  • Nanocomposition Comprising Modified Exatecan And Use Thereofapplication
  • Treatment Of Head And Neck Cancer With Pharmaceutical Composition Comprising Nanoparticles Containing Taxaneapplication
  • Nanocomposition Comprising Modified Exatecan And Use Thereofapplication
  • Antibody-drug Conjugate Comprising Functionalized Polyoxazoline And Use Thereofapplication
  • Pharmaceutical Composition Containing Taxane Nanoaggregates And Use Thereofapplication
  • Nanocomposition Comprising Antibody-drug Conjugate And Use Thereofapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.